GeoVax Labs (GOVX) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Document Information [Line Items]
Entity Central Index Key	0000832489
Entity Registrant Name	GeoVax Labs, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39563
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0455038
Entity Address, Address Line One	1900 Lake Park Drive, Suite 380
Entity Address, City or Town	Smyrna
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30080
City Area Code	678
Local Phone Number	384-7220
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,381,541
Warrants to Purchase Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	GOVXW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	GOVX
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 18,107,019	$ 9,883,796
Grant funds and other receivables	0	182,663
Prepaid expenses and other current assets	52,818	168,689
Total current assets	18,159,837	10,235,148
Property and equipment, net	168,653	147,741
Deposits	11,010	11,010
Total assets	18,339,500	10,393,899
Current liabilities:
Accounts payable	289,438	267,702
Accrued expenses	46,212	359,281
Current portion of notes payable	0	183,326
Total current liabilities	335,650	810,309
Note payable, net of current portion	0	14,738
Total liabilities	335,650	825,047
Commitments (Note 8)
Stockholders’ equity:
Preferred Stock, $.01 par value: Authorized shares – 10,000,000 Series B convertible preferred stock, $1,000 stated value; -0- and 100 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	0	76,095
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 6,381,541 and 3,834,095 at September 30, 2021 and December 31, 2020, respectively	6,382	3,834
Additional paid-in capital	68,630,363	55,294,504
Accumulated deficit	(50,632,895)	(45,805,581)
Total stockholders’ equity	18,003,850	9,568,852
Total liabilities and stockholders’ equity	$ 18,339,500	$ 10,393,899

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000
Common stock, issued (in shares)	6,381,541	3,834,095
Common stock, outstanding (in shares)	6,381,541	3,834,095
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	100
Preferred stock, shares outstanding (in shares)	0	100

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Grant and collaboration revenue	$ 30,414	$ 415,458	$ 220,539	$ 1,572,037
Operating expenses:
Research and development	1,224,362	416,756	2,659,980	1,687,113
General and administrative	757,432	435,013	2,562,641	1,364,650
Total operating expenses	1,981,794	851,769	5,222,621	3,051,763
Loss from operations	(1,951,380)	(436,311)	(5,002,082)	(1,479,726)
Other income (expense):
Interest income	877	90	3,998	902
Interest expense	0	(134,427)	(1,286)	(142,722)
Gain on debt extinguishment	0	0	172,056	0
Total other income (expense)	877	(134,337)	174,768	(141,820)
Net loss	$ (1,950,503)	$ (570,648)	$ (4,827,314)	$ (1,621,546)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.31)	$ (0.73)	$ (0.80)	$ (2.85)
Weighted average shares outstanding (in shares)	6,349,297	782,978	6,005,032	569,955

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Warrants Issued in Bridge Financing [Member]Preferred Stock [Member]	Warrants Issued in Bridge Financing [Member]Common Stock [Member]	Warrants Issued in Bridge Financing [Member]Additional Paid-in Capital [Member]	Warrants Issued in Bridge Financing [Member]Retained Earnings [Member]	Warrants Issued in Bridge Financing [Member]	Warrant Issued for Technology License[Member]Preferred Stock [Member]	Warrant Issued for Technology License[Member]Common Stock [Member]	Warrant Issued for Technology License[Member]Additional Paid-in Capital [Member]	Warrant Issued for Technology License[Member]Retained Earnings [Member]	Warrant Issued for Technology License[Member]	Conversion from Convertible Debentures to Conversion Units [Member]Preferred Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Common Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Additional Paid-in Capital [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Retained Earnings [Member]	Conversion from Convertible Debentures to Conversion Units [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019																2,486	14,992
Balance at Dec. 31, 2019																$ 1,932,433	$ 15	$ 39,340,509	$ (42,847,513)	$ (1,574,556)
Issuance of common stock for services (in shares)																0	521
Issuance of common stock for services																$ 0	$ 1	5,999	0	6,000
Net loss																			(595,694)	(595,694)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)																300
Sale of convertible preferred stock for cash and cancellation of note payable																$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)																(2,386)	674,067
Conversion of preferred stock to common stock																$ (1,856,338)	$ 674	1,855,664
Balance (in shares) at Mar. 31, 2020																400	689,580
Balance at Mar. 31, 2020																$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019																2,486	14,992
Balance at Dec. 31, 2019																$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Net loss																				$ (1,621,546)
Common stock issued for cancellation of accrued compensation (in shares)																				300,001
Balance (in shares) at Sep. 30, 2020																100	3,559,473
Balance at Sep. 30, 2020																$ 76,095	$ 3,559	55,203,149	(44,469,059)	$ 10,813,744
Balance (in shares) at Mar. 31, 2020																400	689,580
Balance at Mar. 31, 2020																$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Issuance of common stock for services (in shares)																0	2,124
Issuance of common stock for services																$ 0	$ 2	11,998	0	12,000
Net loss																$ 0	$ 0	0	(455,204)	(455,204)
Issuance of warrant	$ 0	$ 0	$ 457,833	$ 0	$ 457,833
Balance (in shares) at Jun. 30, 2020																400	691,704
Balance at Jun. 30, 2020																$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Sale of common stock for cash (in shares)																0	2,310,000
Sale of common stock for cash																$ 0	$ 2,310	11,156,186	0	11,158,496
Common stock issued (in shares)																0	36,902
Issuance of common stock for services (in shares)																0	517
Issuance of common stock for services																$ 0	$ 0	6,000	0	6,000
Net loss																$ 0	$ 0	0	(570,648)	(570,648)
Conversion of preferred stock to common stock (in shares)											0	177,626				(300)	42,723
Conversion of preferred stock to common stock											$ 0	$ 177	$ 569,340	$ 0	$ 569,517	$ (300,000)	$ 43	299,957	0	0
Warrants exercised for common stock																$ 0	$ 37	(37)	0	0
Common stock issued for cancellation of accrued compensation (in shares)																0	300,001
Common stock issued upon cancellation of accrued compensation																$ 0	$ 300	1,499,700	0	1,500,000
Balance (in shares) at Sep. 30, 2020																100	3,559,473
Balance at Sep. 30, 2020																$ 76,095	$ 3,559	55,203,149	(44,469,059)	10,813,744
Balance (in shares) at Dec. 31, 2020																100	3,834,095
Balance at Dec. 31, 2020																$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Sale of common stock for cash (in shares)																0	1,644,000
Sale of common stock for cash																$ 0	$ 1,644	9,407,276	0	9,408,920
Common stock issued (in shares)																0	835,900
Issuance of common stock upon warrant exercise																$ 0	$ 836	3,173,320	0	3,174,156
Issuance of common stock for services (in shares)																0	1,472
Issuance of common stock for services																$ 0	$ 1	5,999	0	6,000
Stock option expense																		56,190		56,190
Net loss																			(1,562,778)	(1,562,778)
Balance (in shares) at Mar. 31, 2021																100	6,315,467
Balance at Mar. 31, 2021																$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Balance (in shares) at Dec. 31, 2020																100	3,834,095
Balance at Dec. 31, 2020																$ 76,095	$ 3,834	55,294,504	(45,805,581)	$ 9,568,852
Issuance of common stock for services (in shares)																				13,707
Net loss																				$ (4,827,314)
Balance (in shares) at Sep. 30, 2021																0	6,381,541
Balance at Sep. 30, 2021																$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Mar. 31, 2021																100	6,315,467
Balance at Mar. 31, 2021																$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Issuance of common stock for services (in shares)																0	12,235
Issuance of common stock for services																$ 0	$ 13	65,828	0	65,841
Stock option expense																0	0	56,190	0	56,190
Net loss																$ 0	$ 0	0	(1,314,033)	(1,314,033)
Repurchase of preferred stock (in shares)																(100)	0
Repurchase of preferred stock																$ (76,095)	$ 0	75,095	0	(1,000)
Balance (in shares) at Jun. 30, 2021																0	6,327,702
Balance at Jun. 30, 2021																$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Balance (in shares) at Mar. 31, 2021																100	6,315,467
Balance at Mar. 31, 2021																$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Common stock issued (in shares)																0	53,839
Issuance of common stock upon warrant exercise																$ 0	$ 54	229,946	0	230,000
Stock option expense																$ 0	$ 0	56,190	0	56,190
Balance (in shares) at Sep. 30, 2021																0	6,381,541
Balance at Sep. 30, 2021																$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Jun. 30, 2021																0	6,327,702
Balance at Jun. 30, 2021																$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Net loss																$ 0	$ 0	0	(1,950,503)	(1,950,503)
Issuance of warrant						$ 0	$ 0	$ 209,825	$ 0	$ 209,825
Balance (in shares) at Sep. 30, 2021																0	6,381,541
Balance at Sep. 30, 2021																$ 0	$ 6,382	$ 68,630,363	$ (50,632,895)	$ 18,003,850

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (4,827,314)	$ (1,621,546)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	26,806	2,983
Warrant issued for technology license fee	209,825	0
Gain on debt extinguishment	(172,056)	0
Changes in assets and liabilities:
Grant funds and other receivables	182,663	(72,551)
Prepaid expenses and other current assets	106,979	82,274
Amortization of debt discount	0	124,185
Accounts payable and accrued expenses	(289,477)	252,036
Total adjustments	314,043	412,927
Net cash used in operating activities	(4,513,271)	(1,208,619)
Cash flows from investing activities
Purchase of property and equipment	(47,718)	(2,470)
Net cash used in investing activities	(47,718)	(2,470)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	9,408,920	11,158,496
Net proceeds from sale of preferred stock	0	300,000
Net proceeds from warrant exercises	3,404,156	0
Net proceeds from bridge financing	0	888,500
Net proceeds from issuance of note payable	0	170,200
Repurchase of preferred stock	(1,000)	0
Principal repayment of note payable	(27,864)	(8,854)
Net cash provided by financing activities	12,784,212	12,508,342
Net increase in cash and cash equivalents	8,223,223	11,297,253
Cash and cash equivalents at beginning of period	9,883,796	283,341
Cash and cash equivalents at end of period	18,107,019	11,580,594
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	168,570	0
Consultants [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	$ 80,733	$ 24,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Shares issued (in shares)		716,790
Common stock issued for cancellation of accrued compensation (in shares)		300,001
Deferred compensation		$ 1,500,000
Paycheck Protection Program CARES Act [Member]
Extinguishment of debt	$ 172,056
Conversion from Convertible Debentures to Conversion Units [Member]
Shares issued upon conversion (in shares)		177,626
Convertible debentures		$ 1,200,000
Related accrued interest		$ 14,667
Stock Purchase Warrants First Issuance [Member]
Common stock issued (in shares)	149,705	36,902
Unit Warrants [Member]
Warrant issued (in shares)		300,001
Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Pre-funded stock purchase warrants (in shares)		303,668
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Pre-funded stock purchase warrants (in shares)		126,042

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV- 2 19 On September 28, 2021, 1/2 no not GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at September 30, 2021 three nine September 30, 2021 2020 not 10 December 31, 2020. not We enacted reverse stock splits of our common stock on September 25, 2020 ( 1 January 21, 2020 ( 1 Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the twelve may may no

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2020 nine September 30, 2021, no 10 no

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share totaled 2,965,451 and 2,550,184 shares for the three nine September 30, 2021, three nine September 30, 2020,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281

Note 7 - Notes Payable

Note 7 - Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable GRA Note February 28, 2018, five five three nine September 30, 2021 2020. May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one three nine September 30, 2021, 2020. May 2021,

Note 8 - Commitments

Note 8 - Commitments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. three nine September 30, 2021 2020. 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of September 30, 2021, 2021.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	9. Stockholders Equity Preferred Stock June 7, 2021, September 30, 2021, Public Offering February 11, 2021, Stock Options “2020 may 2020 nine September 30, 2021, no 2020 September 30, 2021, Stock Purchase Warrants January February 2021, During August 2021, On September 28, 2021, five As of September 30, 2021, Other Common Stock Transactions nine September 30, 2021,

Note 10 - Stock-based Expense

Note 10 - Stock-based Expense	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Stock-Based Expense Stock-based compensation expense related to employee and director stock options was $56,190 and $168,570 during the three nine September 30, 2021, 2020. September 30, 2021, During the three nine September 30, 2021, 2020. September 30, 2021, During September 2021,

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not 382 may

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2021, 2020. three nine September 30, 2020, third September 30, 2021, 2022.

Note 13 - Subsequent Event

Note 13 - Subsequent Event	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event On November 9, 2021, 19 30 first second

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Sep. 25, 2020	Jan. 21, 2020
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20	2,000

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	2,965,451	204,553	2,550,184	78,754

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 707,159	$ 659,441
Accumulated depreciation and amortization	(538,506)	(511,700)
Property and equipment, net	168,653	147,741
Equipment and Furnishings [Member]
Property and equipment, gross	591,554	543,836
Leasehold Improvements [Member]
Property and equipment, gross	$ 115,605	$ 115,605

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued salaries	$ 11,212	$ 279,696
Other accrued expenses	35,000	79,585
Total accrued expenses	$ 46,212	$ 359,281

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	May 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Notes Payable, Total						$ 0	$ 170,200
Repayments of Notes Payable						27,864	8,854
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Interest Expense, Debt, Total				$ 0	$ 429	653	774
Extinguishment of Debt, Amount			$ 170,200
Gain (Loss) from Interest Forgiven			1,856
Senior Notes [Member]
Debt Instrument, Term (Year)		5 years
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Interest Expense, Debt, Total				$ 0	$ 411	$ 633	$ 1,344
Repayments of Notes Payable			$ 22,737

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)
Unrecorded Unconditional Purchase Obligation, Total	$ 607,000		$ 607,000
Office and Laboratory Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Lease, Expense	$ 42,803	$ 41,539	$ 128,410	$ 124,617
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	42,803		42,803
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 176,356		$ 176,356

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 07, 2021	Feb. 11, 2021	Aug. 31, 2021	Feb. 28, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 28, 2021	Dec. 31, 2020
Stock Repurchased During Period, Value					$ 1,000
Stock Issued During Period, Shares, New Issues (in shares)		1,644,000
Shares Issued, Price Per Share (in dollars per share)		$ 6.25
Proceeds from Issuance of Common Stock		$ 9,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						602,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)						$ 2.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)						9 years 2 months 12 days
Proceeds from Warrant Exercises			$ 230,000	$ 3,174,156		$ 3,404,156	$ 0
Stock Issued During Period, Shares, Issued for Services (in shares)						13,707
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)						1,500,000
Representative Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		72,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.875
Stock Purchase Warrants First Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			27,004	188,688
Stock Issued During Period, Shares, Warrants Exercised (in shares)			3,839	145,866		149,705	36,902
Stock Purchase Warrants Second Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			50,000	690,034
Stock Issued During Period, Shares, Warrants Exercised (in shares)			50,000	690,034
Stock Purchase Warrant to PNP [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 13
Warrants and Rights Outstanding, Term (Year)								5 years
Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 5.35
Warrants and Rights Outstanding, Term (Year)						3 years 10 months 24 days
Class of Warrant or Right, Outstanding (in shares)						2,816,631
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		204,000
Series B Convertible Preferred Stock [Member]
Stock Repurchased During Period, Shares (in shares)	100
Stock Repurchased During Period, Value	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						0			100

Note 10 - Stock-based Expense (

Note 10 - Stock-based Expense (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 486,940	$ 486,940		$ 486,940
Stock Issued During Period, Value Expensed During the Period, Issued for Services		29,560	$ 6,000	80,733	$ 24,000
Prepaid Expense, Value of Stock Issued for Services During Period	39,773	39,773		39,773
Research and Development Expense [Member]
Warrant Issuance Expense	$ 209,825
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 56,190	$ 0	$ 168,570	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 2 months 12 days

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Income Taxes Paid	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	$ 415,458	$ 220,539	$ 1,572,037
Unused Grant Funds	244,888		244,888
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	231,330	$ 220,539	1,186,844
Leidos, Inc. Research Collaborative Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 184,128		$ 385,193

Note 13 - Subsequent Event (Det

Note 13 - Subsequent Event (Details Textual) - City of Hope [Member] - Subsequent Event [Member]	Nov. 09, 2021USD ($)
Upfront Fee	$ 5,000,000
License First Anniversary Payment [Member]
License Fees	3,000,000
License Second Anniversary Payment [Member]
License Fees	$ 2,000,000